Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ovarian Cancer
Clinical trial register · Spain

Ovarian Cancer Trials in Spain, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5882 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:19 UTC
5882
Studies in scope
all four open statuses
3093
Recruiting now
open to new participants
1126
Lead sponsors
across recruiting studies
Top sites
Madrid 32 Barcelona 30 Málaga 10 Valencia 10 Girona 8
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca7 AbbVie3 Merck Sharp & Dohme LLC2 Incyte Corporation2 K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc1 Regeneron Pharmaceuticals1 MedSIR1 Xencor, Inc.1 Genmab1 Oncare Madrid1 CanariaBio Inc.1 Oncoinvent Solutions AS1 ARCAGY/ GINECO GROUP1 BioInvent International AB1 Theolytics Limited1 Artios Pharma Ltd1 Terremoto Biosciences Inc.1 Daiichi Sankyo1 North Eastern German Society of Gynaecological Oncology1 Verastem, Inc.1 Corcept Therapeutics1 BicycleTx Limited1 Hoffmann-La Roche1 Complejo Hospitalario Universitario Insular Materno Infantil1 Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia1 Show all 29
Site location
Madrid32 Barcelona30 Málaga10 Valencia10 Girona8 Córdoba8 A Coruña7 Pamplona6 Seville5 L'Hospitalet de Llobregat4 Oviedo3 Badalona3 Donostia / San Sebastian3 Granada2 Majadahonda2 Sabadell2 Santander2 Pozuelo de Alarcón2 El Palmar2 Palma2 Las Palmas de Gran Canaria2 Murcia2 Vigo1 Santiago de Compostela1 Barakaldo1 Show all 37
All 37 locations
Target enrolment
to

Ovarian Cancer trials in Spain

39 of 5882 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Not yet open
Oncare Madrid
Not applicable
32
Madrid
2028-05
Recruiting
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 3
420
Barcelona, Madrid, Málaga, Vigo
2026-04-17
Recruiting
Genmab
Phase 3
544
A Coruña
2026-04-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
900
Girona, A Coruña, Madrid, Valencia, Barcelona, Córdoba
2026-02-16
Recruiting
AstraZeneca
Phase 1
32
Barcelona, Logroño, Madrid
2026-01-26
Recruiting
Hospital Vall d'Hebron
Not applicable
152
Barcelona
2026-01-01
Recruiting
Incyte Corporation
Phase 3
466
Alava, Badalona, Barcelona, Madrid, Málaga, Oviedo, Palma, Sabadell
2025-12-09
Recruiting
AbbVie
Phase 1
285
Majadahonda, Barcelona, Madrid
2025-11-27
Recruiting
AbbVie
Phase 2
400
Santander, Donostia / San Sebastian, Las Palmas de Gran Canaria, Majadahonda, Seville, A Coruña, Barcelona, Girona
2025-11-13
Recruiting
Incyte Corporation
Phase 2
160
Barcelona, Córdoba, Girona, Madrid, Murcia, Valencia
2025-11-12
Recruiting
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT07109726Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma
DrugFulvestrant
Terremoto Biosciences Inc.
Phase 1/2
248
Barcelona, Madrid
2025-09-23
Recruiting
Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian Cancer
NCT07100288Ovarian Cancer, Ovarian Cancer (OvCa), Ovarian Adenocarcinoma
Complejo Hospitalario Universitario Insular Materno Infantil
Observational
200
Las Palmas de Gran Canaria
2025-07-20
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
DrugsNab-paclitaxel /m^2·Relacorilant·Bevacizumab
Corcept Therapeutics
Phase 2
270
Badalona, Barcelona, Madrid, Valencia
2025-04-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Girona, Madrid, Valencia, Barcelona, Córdoba
2025-04-09
Recruiting
Daiichi Sankyo
Phase 3
582
A Coruña, Barcelona, Córdoba, Donostia / San Sebastian, El Palmar, Girona, Madrid, Palma
2025-03-19
Recruiting
Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression
NCT06180356Ovarian Cancer, Oligometastatic Disease, Serous Ovarian Tumor
DrugNiraparib
MedSIR
Phase 2
30
A Coruña, Barakaldo, Barcelona, Girona, Jaén, Madrid, Málaga, Oviedo
2024-12-03
Recruiting
North Eastern German Society of Gynaecological Oncology
Phase 2
640
Alicante, Granada, Lugo, Madrid, Manresa, Seville, Tarragona, Valencia
2024-10-11
Recruiting
Theolytics Limited
Phase 1/2
44
Madrid
2024-09-24
Recruiting
Oncoinvent Solutions AS
Phase 2
114
Barcelona, Madrid, Pamplona, Valencia
2024-06-15
Recruiting
Gilead Sciences
Phase 1/2
334
Madrid
2024-06-12
Recruiting
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT06276491Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor
DrugXmAb541
Xencor, Inc.
Phase 1
282
Barcelona, Madrid, Pamplona
2024-04-04
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
622
Barcelona, Madrid, Málaga
2023-06-05
Active, closed
AbbVie
Phase 3
520
A Coruña, L'Hospitalet de Llobregat, Córdoba, Málaga, Pamplona, Barcelona, Girona, Madrid
2023-03-15
Recruiting
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Not applicable
20
Murcia
2023-02-27
Recruiting
AstraZeneca
Phase 2
454
Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville
2022-09-06
Recruiting
ARCAGY/ GINECO GROUP
Phase 2
390
A Coruña, Barcelona, Cáceres, El Palmar, Murcia, Jerez de la Frontera, Madrid, Málaga, Oviedo
2022-02-01
Recruiting
AstraZeneca
Phase 1/2
460
Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona
2021-10-18
Active, closed
Hoffmann-La Roche
Phase 2
176
Barcelona, Madrid, Málaga
2021-10-07
Active, closed
Pfizer
Phase 3
77
Barcelona, L'Hospitalet de Llobregat, Madrid, Seville
2021-09-29
Recruiting
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer
DrugsIrinotecan·Gemcitabine
Artios Pharma Ltd
Phase 1/2
542
Elche, Sabadell, Santander, Barcelona, Lleida, Madrid, Pozuelo de Alarcón, El Palmar
2021-01-27
Recruiting
BioInvent International AB
Phase 1/2
250
Barcelona, Madrid
2021-01-25
Active, closed
Verastem, Inc.
Phase 2
225
Barcelona, Córdoba, Madrid, Valencia
2020-12-21
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
612
Santiago de Compostela, Girona, Madrid
2020-12-08
Active, closed
AstraZeneca
Phase 1/2
702
Barcelona, Madrid, Málaga, Pozuelo de Alarcón, Seville
2020-11-12
Active, closed
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
NCT04498117Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma
DrugsOregovomab·Paraplatin·Taxol·Paclitaxel
CanariaBio Inc.
Phase 3
615
Barcelona, L'Hospitalet de Llobregat, Valencia
2020-08-25
Active, closed
AstraZeneca
Phase 3
185
Badalona, Barcelona, Córdoba, Donostia / San Sebastian, Granada, Madrid, Pamplona, Valencia
2020-08-04
Active, closed
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer
DrugsNuzefatide pevedotin·Opdivo·Nivolumab
BicycleTx Limited
Phase 1/2
288
Barcelona, Madrid
2019-11-07
Active, closed
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT02489006Ovarian Cancer, Fallopian Tube Cancer, Neoadjuvant Treatment, Debulking Surgical Procedures
DrugOlaparib
University Health Network, Toronto
Phase 2
71
Barcelona
2016-07-19
Active, closed
AstraZeneca
Phase 2
162
Madrid, Valencia
2010-02-04
Rows per page Showing 1–39 of 39
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-spain/condition/ovarian-cancer

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,882 studies in total at the last sync on 10 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 39 of those studies listing the condition Ovarian Cancer.

How many Ovarian Cancer trials are recruiting in Spain?

28 of the 39 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:19 UTC sync. A further 1 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ovarian Cancer), 39 studies
PhaseStudiesRecruitingShare
Phase 212830.8%
Phase 1/210825.6%
Phase 310625.6%
Not applicable327.7%
Phase 1337.7%
Observational112.6%

Most active sponsors

Lead sponsors with the most studies (Ovarian Cancer)
Lead sponsorStudiesRecruiting
AstraZeneca74
AbbVie32
Incyte Corporation22
Merck Sharp & Dohme LLC22
ARCAGY/ GINECO GROUP11
Artios Pharma Ltd11
BicycleTx Limited10
BioInvent International AB11
CanariaBio Inc.10
Complejo Hospitalario Universitario Insular Materno Infantil11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.